← All Nascent Biotech INC filings

Nascent Biotech INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
NBIO
Nascent Biotech INC
10-Q: Nascent Biotech Reports Q1 2025 Results, Progresses to Phase 2 Clinical Trials
Nascent Biotech has completed Phase 1 clinical trials for its cancer treatment Pritumumab and is preparing to begin Phase 2 trials, while reporting a net loss of $377,390 for the quarter ending June 30, 2024.
OTC.Pink
NBIO
Nascent Biotech INC
10-Q: Nascent Biotech Reports Q3 2024 Results, Advances Brain Cancer Clinical Trials
Nascent Biotech reports its financial results for the quarter ended December 31, 2023, highlighting progress in its Phase 2 clinical trials for brain cancer and ongoing financial challenges.